David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, speaks on the difficulties of gaining coverage for newer biologic therapies in the treatment of atopic dermatitis.
Since non-severe cases of atopic dermatitis are not typically associated with hospitalization, creative strategies are warranted to show how emerging biologic therapies can improve treatment outcomes and lead to substantial cost savings in seeking reimbursement, said David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology.
Transcript
If these newer treatments for atopic dermatitis are beneficial, are you concerned about access and affordability, in particular for patients with Medicaid coverage?
Always, yes. So, we need to figure all this out, and that's going to come along with the process and with time. We have some wonderful education for the use of these biologic agents in the world of asthma and we know that insurance companies are often much more likely to reimburse it and pay it for patients who have severe disease and recurrent hospitalization.
So, if we can demonstrate that we're going to save them money in the long run, that's generally the best way to sort of get better coverage. It may be a bit of a tougher sell when it comes to atopic dermatitis. In general, those patients don't tie up hospital beds or ER [emergency room] visits or things like that. We’re going to have to get creative in some regards, but I'm hopeful that these will be covered.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More